Moleculin Biotech receives Mexican patent for Annamycin until 2040
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
Go back to Moleculin Biotech receives Mexican patent for Annamycin until 2040
September 23, 2026 8:25 AM EDT
Strengthens Global Intellectual Property Estate for Annamycin's Proprietary Liposomal Formulation Designed to Target Lung Metastases While Supporting Long-Term Commercial Opportunity
HOUSTON, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), today announced that the Mexican Patent Office has granted Patent No. 436849, further strengthening the Company's global intellectual property portfolio protecting its proprietary lung-targeted liposomal Annamycin technology.
The newly issued patent supports Moleculin's strategy of building a robust worldwide intellectual property estate around Annamycin, the Company's highly efficacious and well tolerated anthracycline... More
